Andrew Charles
Neurology · Los Angeles, CANPI 1518982453
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.4%. 2025 is the largest year on record at $65,004, 10.0 times the $6,503 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $1821.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- H. Lundbeck A S$23K
- Amgen$21K
- Lilly USA, LLC$20K
- Lundbeck LLC$18K
- Pfizer$18K
- plus $17K from 6 others
Across 2 payments — averaging $1824.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
- Pfizer$330
What the payments were for
- Consulting fees$86,43058%
- Speaking & faculty fees$50,03333%
- Travel & lodging$11,4658%
- Food & beverage$1,4371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $31,923 |
| H. Lundbeck A S | 15 | $22,721 |
| Amgen | 10 | $21,056 |
| Lilly USA, LLC | 5 | $20,038 |
| Lundbeck LLC | 6 | $18,275 |
| Pfizer | 8 | $18,089 |
| UCB SA | 2 | $5,170 |
| Biodelivery Sciences International, Inc. | 1 | $3,000 |
| Eli Lilly | 2 | $2,753 |
| Pfizer S.A. | 1 | $2,700 |
| Boehringer Ingelheim International GmbH | 3 | $2,642 |
| Biogen | 1 | $1,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$29,809
- AIMOVIG$21,056
- QULIPTA$20,904
- NURTEC ODT$20,668
- EMGALITY$9,425
- REYVOW$9,163
- UBRELVY$3,304
- ELYXYB - CELECOXIB$3,000
- BOTOX$716
How this compares
$149,365 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dihydroergotamine Mesylate | 12 | $18,761 |
| Emgality PenGalcanezumab-Gnlm | 15 | $12,290 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.